...
首页> 外文期刊>British Journal of Cancer >Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation
【24h】

Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation

机译:适用于肿瘤特异性前药激活的融合蛋白的分子和功能表征

获取原文
   

获取外文期刊封面封底 >>

       

摘要

A fusion protein consisting of the humanised Fab fragment of the anti CEA MAb BW 431 and the human beta-glucuronidase was expressed in BHK cells. Functional testing revealed that the specificity and avidity of the humanised V region was similar to the original murine MAb BW 431. Furthermore, the enzymatic activity, pH sensitivity and stability of the human beta-glucuronidase in the fusion protein was comparable to the activity of recombinant human beta-glucuronidase. Using anti-idiotype affinity chromatography, two molecules of a molecular weight of 125 kDa or 250 kDa could be visualized under nonreducing conditions in SDS-PAGE. Reducing conditions revealed a 25 kDa light and 100 kDa heavy chain. Due to its suitable biological characteristics this fusion protein might be an appropriate molecule allowing a site specific antibody directed enzyme prodrug therapy (ADEPT) in vivo.
机译:在BHK细胞中表达了由抗CEA MAb BW 431的人源化Fab片段和人β-葡糖醛酸糖苷酶组成的融合蛋白。功能测试表明,人源化V区的特异性和亲和力与原始鼠单克隆抗体BW 431相似。此外,人β-葡萄糖醛酸苷酶在融合蛋白中的酶促活性,pH敏感性和稳定性与重组体的活性相当。人β-葡萄糖醛酸苷酶。使用抗独特型亲和色谱,可以在非还原条件下在SDS-PAGE中观察到分子量为125 kDa或250 kDa的两个分子。还原条件显示出25 kDa的轻链和100 kDa的重链。由于其合适的生物学特性,该融合蛋白可能是允许在体内进行位点特异性抗体指导的酶前药治疗(ADEPT)的合适分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号